Regen BioPharma Inc
Raising nowPublicBiotech · La Mesa, CA
Regen BioPharma develops regenerative medical therapies, mainly for cancer, which it licenses, builds in-house or acquires and takes through Phase I/II trials before selling, licensing or advancing them. Its patent portfolio covers gene silencing, NR2F6 inhibition, cord blood killer cells and mRNA cancer vaccines. It has licensed veterinary rights to affiliate Zander Therapeutics.
This company has an open fundraising round.
Financials
FY2013–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 5 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
“Today's shares” restates every price in the share terms current now, so a price before a split or an LLC→corporation conversion is divided by that event's ratio (each event is cited on the round page). Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Aug 12, 2026These classes don't convert into each other and last sold at very different prices, so their share counts can't be added up into ownership percentages. Compare them by price instead.
| Class | Outstanding | Votes / share | Last price |
|---|---|---|---|
| Series A Preferred Stockpreferred | 170,081,498 | — | $15.00Feb 2018 |
| Series M Preferredpreferred | 29,338 | — | — |
| Series AA Preferred Stockpreferred | 15,007 | — | — |
| Series N Preferred Stockpreferred | 800 | — | — |
| Common Stock | 1,675,277,503 | — | $0.0045Dec 2025 |
Principal holders% as the filing states it, Jan 8, 2026
- based on15,007 Series NC Preferred100.0%of company
- David R. Koos15,007 Series NC Preferred100.0%of Series NC Preferred
- David R. Koos27,436,799 Common27.0%of
- David R. Koos7,667 Series M Preferred26.1%of Series M Preferred
- Todd S. Caven6,667 Series M Preferred22.7%of Series M Preferred
- Harry Lander6,667 Series M Preferred22.7%of Series M Preferred
- c/o Regen Biopharma, Inc6,667 Series M Preferred22.7%of company
- Harry Lander20,020,001 Common19.4%of
- Jean-Pierre Millon4,001 Series M Preferred13.6%of Series M Preferred
- Roger Formisano2,001 Series M Preferred6.82%of Series M Preferred
- Robert D. Hopkins2,001 Series M Preferred6.82%of Series M Preferred
- David R. Koos413,288 Series A Preferred4.08%of Series A Preferred
- c/o Regen Biopharma413,288 Series A Preferred4.08%of company
Sold to the crowd
- Reg A+ · Sep 2024291,000 Common Stock at $0.20$58.2K
- Reg A+ · Aug 2025680,000 shares at $0.10$68K
- Reg A+ · Dec 20257,777,778 Common Stock at $0.0045$35K
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
SEC filings
View all 79 filings on EDGAR- Form 10-QAug 17, 20260001493152-26-038576EDGAR
- Form 10-QMay 14, 20260001493152-26-022924EDGAR
- Form 10-QFeb 13, 20260001493152-26-006526EDGAR
- Form QUALIFJan 12, 20269999999994-26-000013EDGAR
- Form 1-A POSJan 8, 20260001493152-26-000934EDGAR
- Form 10-KDec 30, 20250001493152-25-029526EDGAR
- Form 253G1Dec 5, 20250001493152-25-026350EDGAR
- Form QUALIFDec 3, 20259999999994-25-000213EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.